Adjunctive esketamine appears effective for patients with major depressive disorder (MDD) who are treatment-resistant or suicidal, a meta-analysis published in The Journal of Clinical Psychiatry concluded.
A novel vasopressin 1B (V1B) receptor antagonist eased depressive symptoms when used as an adjunctive treatment in patients with major depressive disorder (MDD) in a small phase 2 study in the Journal of Psychiatric Research.
Depression is “vastly underdiagnosed” in people with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), states a literature review published online in the Harvard Review of Psychiatry.
The protein GPR56 may provide an easy-to-measure biomarker of a patient’s response to antidepressants as well as a novel drug target for the treatment of major depressive disorder, according to a published study.
The US Food and Drug Administration (FDA) recently granted Usona Institute, Madison, Wisconsin, the Breakthrough Therapy designation for psilocybin in the treatment of patients with major depressive disorder (MDD).
SAN DIEGO—Mental health clinicians aren't talking to their patients enough about sexual dysfunction commonly associated with depression and its treatment, Anita Clayton. MD, stated at Psych Congress 2019.
SAN DIEGO—Added to standard-of-care treatment, esketamine nasal spray rapidly reduced depressive symptoms in patients at imminent risk of suicide, according to two phase 3 trials presented at Psych Congress 2019.